The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday, June 21, 2017.
Diageo to Acquire Casamigos for $700M Upfront, $300M in Performance-Related Payments
The Deal:
Diageo plc (ADR) (NYSE: DEO) will
acquire Casamigos, the tequila brand founded by Rande Gerber, George Clooney and Mike Meldmani. The purchase price is $1
billion, plus up to $300 million in performance-based payments over 10 years.
The transaction is expected to close in the second half of 2017.
Diageo closed at $121.75, down $0.43.
Traders Circulate Chatter of Pfizer in Talks to Acquire Bristol-Myers Squibb
The Rumor:
Shares of Bristol-Myers Squibb Co (NYSE: BMY) spiked to a high of $56.58 as traders circulated unconfirmed market chatter of a
potential offer from Pfizer Inc. (NYSE: PFE).
"Sources" say Pfizer could bid as high as $75 in cash and stock for the maker of Opdivo and Yervoy.
Carl Icahn took a stake in Bristol-Myers Squibb in February.
Bristol-Myers Squibb closed at $56.07, up $0.41.
Traders Circulate Chatter of Biogen Interest in Acadia
The Rumor:
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded as high as $30.22, with traders circulating unconfirmed market chatter
of a bid from Biogen Inc (NASDAQ: BIIB).
"Sources" say the bid could be $42.00 per share.
In February, various reports said the biotech company had been approached by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ)
Acadia closed at $29.27, up $1.05.
Sycamore Partners in Advanced Talks to Acquire Staples
The Rumor:
Sycamore Partners is in advanced talks to acquire Staples, Inc. (NASDAQ: SPLS), according to a report from Reuters late Wednesday. A deal could be valued at
more than $6 billion and could be announced next week, sources said.
Sycamore beat out Cerberus Capital Managements in an auction process and is finalizing a debt financing package for the deal,
according to three sources said.
Staples and Sycamore declined comment on the report.
Staples closed at $8.66 and traded at $9.13 after-hours.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.